{"filing":{"accession_number":"0001828318-26-000050","cik":"0001828318","ticker":"ENVX","company_name":"Enovix Corp","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"envx-20260709.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828318/000182831826000050/envx-20260709.htm"},"events":[{"id":17259,"run_id":15442,"accession_number":"0001828318-26-000050","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Enovix announced the appointment of Dr. Michael Vyvoda as Chief Operating Officer, effective July 29, 2026. The disclosure details his background, compensation package ($440,000 base salary plus 60% bonus target and $4.1 million in RSUs), and severance terms. While the filing includes compensatory arrangements, the principal disclosed action is the appointment of a named executive officer to a C-suite role, making exec_appointment the most salient classification.","company_name":"Enovix Corp","ticker":"ENVX","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15633,"accession_number":"0001828318-26-000050","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Enovix announced the appointment of Dr. Michael Vyvoda as Chief Operating Officer, effective July 29, 2026. The disclosure details his background, compensation package ($440,000 base salary plus 60% bonus target and $4.1 million in RSUs), and severance terms. While the filing includes compensatory arrangements, the principal disclosed action is the appointment of a named executive officer to a C-suite role, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:07:51.630493+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15633,"accession_number":"0001828318-26-000050","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Enovix announced the appointment of Dr. Michael Vyvoda as Chief Operating Officer, effective July 29, 2026. The disclosure details his background, compensation package ($440,000 base salary plus 60% bonus target and $4.1 million in RSUs), and severance terms. While the filing includes compensatory arrangements, the principal disclosed action is the appointment of a named executive officer to a C-suite role, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:07:51.630493+00:00","company_name":"Enovix Corp","ticker":"ENVX","filing_date":"2026-07-09"}]}